On these pages you can check out the latest breast cancer news from BCAC and our member groups. We also provide up-to-date information and links to current breast cancer research and clinical trials. Read latest stories below, or use the filters or the pager below for other stories. Use the form to the right of this to subscribe to our e-News.
A clinical trial shows that tucatinib, an investigative therapy used in combination with trastuzumab and capecitabine, reduces risk of death at two years by one-third in women with HER2-positive metastatic breast cancer (HER2+ MBC).
Initial trial results on the cost and effectiveness of MRI breast cancer screening compared to mammography, in women with a familial risk, have been presented at the San Antonio Breast Cancer Symposium. The FaMRIsc study is the first randomised trial that has made this comparison.
Progress continues to be made through world-leading research to identify which treatments will work best for different sub-types of breast cancer.
In brilliant news, it has been discovered that adding ribociclib to first-line endocrine therapy significantly improves both progression free and overall survival (PFS and OS) for premenopausal women with advanced breast cancer.
The Waikato Breast Cancer Research Trust (WBCRT) is seeking participants with moderately severe treatment-resistant lymphoedema for this research. Is lymphoedema of your arm an ongoing problem for you? Have you undergone at least three months of lymphoedema therapy?
Key findings announced at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago include breakthroughs in the treatment of breast cancer and research. In a series of articles including this one, we outline some of the exciting developments reported.
In an exciting breakthrough, a very important protein has been discovered that predicts whether a breast cancer patient is going to respond successfully to endocrine therapy or chemotherapy.
We note that PHARMAC reported in June 2017 that the special $3.2 million fund they set up in 2007 to fund the SOLD Herceptin trial to...
BCAC is thrilled a clinical trial involving American engineer Judy Perkins has led to her being declared free of breast cancer with what specialists are calling an extended remission. This wonderful news has come two years after she was told she had only three months to live.
The trial of the experimental therapy was carried out by the US National Cancer Institute. BCAC are aware there is still much to learn before scientists can turn this experimental therapy into a treatment.